| CRIS Market Cap History Table | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Below is a table of the CRIS market cap history going back to 5/30/2018:
Also see: CRIS Shares Outstanding History and CRIS YTD Return |
CRIS Market Cap History — Curis Capitalization Over Time
As of 5/8/2026 Curis has a market cap of 21.83 million. Investors often follow the CRIS market cap history to compare the size of the company over time.
This page shows CRIS market capitalization trends over time, with 34 market cap datapoints presented, dating back to 5/30/2018.
| CRIS Market Cap History Chart | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CRIS Historical Market Cap: -21.79% CAGR 
Mouse over chart for data details
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| CRIS Stock Price Chart |
| About Curis Inc |
| Curis, Inc. is a biotechnology company. Co. is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). Its other clinical programs include Fimepinostat and CA-170. We show 34 historical shares outstanding datapoints in our CRIS shares outstanding history coverage, used to compute CRIS market cap on those dates. Understanding the changing numbers of shares outstanding, the changing share price, and the resulting changing CRIS market cap history over the course of time is important for investors interested in comparing CRIS's market cap history versus its peers. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies, and then calculating their respective market caps. Comparing the share price of CRIS versus a peer is one thing; comparing CRIS market cap versus a peer is a completely different story. Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares), the market cap for a company like CRIS can fluctuate over the course of history. With this page we aim to empower investors researching CRIS by allowing them to research the CRIS market cap history. |
| CRIS Current Stock Quote |
Quotes delayed 20 minutes  Free CRIS Email Alerts:
Get Dividend Alerts 
Get SEC Filing Alerts
|
| Video: The Importance of Market Cap | |
|
Video: The Importance of Market Cap
| CRIS Share Performance |
| Market Cap Peers |
| Curis (CRIS) is categorized under the Healthcare sector; to help you further research historical market cap numbers, below are some other companies in the same sector:
CRL Market Cap History CRMD Market Cap History CRNX Market Cap History CRTX Market Cap History CRVL Market Cap History CRVO Market Cap History CRVS Market Cap History CRY Market Cap History CSBR Market Cap History CSII Market Cap History More Healthcare companies » |
CRIS Market Cap History | www.MarketCapHistory.com | Copyright © 2017 - 2026, All Rights Reserved
Nothing in MarketCapHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you
agree to the following Full Disclaimer & Terms of Use and
Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at
least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
